Yamamoto H, Terasawa T, Ohki A, Shirai F, Kawabata K, Sakane K, Matsumoto S, Matsumoto Y, Tawara S
Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co. Ltd, Kashima, Osaka, Japan.
Bioorg Med Chem. 2000 Jan;8(1):43-54. doi: 10.1016/s0968-0896(99)00257-6.
A series of 7beta-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamid o]-3-[(E)- and (Z)-2-substituted vinyl]-3-cephem-4-carboxylic acids was designed and synthesized using palladium-catalyzed coupling reactions of a 3-methanesulfonyloxy-3-cephem and an E substituted vinyl stannane or Wittig reaction of a 3-triphenylphosphoniummethyl cephem and an aldehyde as a key step. These compounds were evaluated for in vitro antibacterial activity and oral absorption in rats. A number of them exhibited excellent antibacterial activity against both gram-positive and gram-negative bacteria including Haemophilus influenzae. Among them, FR86524 (2j). having a (Z)-2-(3-pyridyl)vinyl moiety at the C-3 position, had the most well balanced activity. Although FR86254 exhibited low oral absorption, the pivaloyloxymethyl ester (23) of FR86524 showed improved oral absorption.
设计并合成了一系列7β-[(Z)-2-(2-氨基噻唑-4-基)-2-羟基亚氨基乙酰胺基]-3-[(E)-和(Z)-2-取代乙烯基]-3-头孢烯-4-羧酸,该合成过程以3-甲磺酰氧基-3-头孢烯与E-取代乙烯基锡烷的钯催化偶联反应或3-三苯基膦甲基头孢烯与醛的维蒂希反应作为关键步骤。对这些化合物进行了体外抗菌活性和大鼠口服吸收评估。其中许多化合物对革兰氏阳性菌和革兰氏阴性菌包括流感嗜血杆菌均表现出优异的抗菌活性。其中,在C-3位具有(Z)-2-(3-吡啶基)乙烯基部分的FR86524(2j)活性最为平衡。尽管FR86254口服吸收较差,但FR86524的新戊酰氧基甲酯(23)口服吸收有所改善。